These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18951621)

  • 21. [Dysregulation of cooperative interactions of immunocytes and eosinophils in the mechanism of development of eosinophilia in Opisthorhis felineus invasion].
    Litvinova LS; Riazantseva NV; Novitskiĭ VV
    Med Parazitol (Mosk); 2008; (3):13-7. PubMed ID: 18819423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
    Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
    J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab.
    Landi C; Cameli P; Vantaggiato L; Bergantini L; d'Alessandro M; Perruzza M; Carleo A; Shaba E; Di Giuseppe F; Angelucci S; Bargagli E; Bini L
    Biochim Biophys Acta Proteins Proteom; 2021 Feb; 1869(2):140563. PubMed ID: 33176218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-interleukin-5 therapy and severe asthma.
    Gleich GJ
    N Engl J Med; 2009 Jun; 360(24):2577; author reply 2578. PubMed ID: 19522047
    [No Abstract]   [Full Text] [Related]  

  • 25. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
    Harish A; Schwartz SA
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
    Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS
    Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor.
    Molfino NA; Gossage D; Kolbeck R; Parker JM; Geba GP
    Clin Exp Allergy; 2012 May; 42(5):712-37. PubMed ID: 22092535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
    Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eosinophils in asthma--closing the loop or opening the door?
    Wenzel SE
    N Engl J Med; 2009 Mar; 360(10):1026-8. PubMed ID: 19264692
    [No Abstract]   [Full Text] [Related]  

  • 30. No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients.
    Oldhoff JM; Darsow U; Werfel T; Bihari IC; Katzer K; Laifaoui J; Plötz S; Kapp A; Knol EF; Bruijnzeel-Koomen CA; Ring J; de Bruin-Weller MS
    Int Arch Allergy Immunol; 2006; 141(3):290-4. PubMed ID: 16931891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of mepolizumab on peripheral circulation and neurological symptoms in eosinophilic granulomatosis with polyangiitis (EGPA) patients.
    Kitamura N; Hamaguchi M; Nishihara M; Ikumi N; Sugiyama K; Nagasawa Y; Tsuzuki H; Yoshizawa S; Tanikawa Y; Oshima M; Asatani S; Kobayashi H; Takei M
    Allergol Int; 2021 Jan; 70(1):148-149. PubMed ID: 32967778
    [No Abstract]   [Full Text] [Related]  

  • 32. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
    Simon D; Braathen LR; Simon HU
    Pathobiology; 2005; 72(6):287-92. PubMed ID: 16582580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab.
    Kuruvilla M
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):670-671. PubMed ID: 29496465
    [No Abstract]   [Full Text] [Related]  

  • 35. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab.
    Pouliquen IJ; Kornmann O; Barton SV; Price JA; Ortega HG
    Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1015-27. PubMed ID: 26445140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin 5 activity in sera from patients with eosinophilia.
    Enokihara H; Kajitani H; Nagashima S; Tsunogake S; Takano N; Saito K; Furusawa S; Shishido H; Hitoshi Y; Takatsu K
    Br J Haematol; 1990 Aug; 75(4):458-62. PubMed ID: 2206996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
    Katz LE; Gleich GJ; Hartley BF; Yancey SW; Ortega HG
    Ann Am Thorac Soc; 2014 May; 11(4):531-6. PubMed ID: 24606022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological and hematological effects of IL-5(Rα)-targeted therapy: An overview.
    Hassani M; Koenderman L
    Allergy; 2018 Oct; 73(10):1979-1988. PubMed ID: 29611207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media.
    Iino Y; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Kanazawa H; Yoshida N
    Acta Otolaryngol; 2014 Apr; 134(4):366-72. PubMed ID: 24628335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reslizumab for pediatric eosinophilic esophagitis.
    Walsh GM
    Immunotherapy; 2010 Jul; 2(4):461-5. PubMed ID: 20636000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.